Industry bodies respond to Specialised Committee outcome
News
Opdivo plus Yervoy combo approved in EU for first-line lung cancer
New approval marks third indication for an Opdivo plus Yervoy-based regimen in the EU
New pricing models could improve access to innovative cancer drugs
Conclusions made by a group of experts from academia and industry
US green lights AZ’s Brilinta to reduce risk of stroke
Approval is based on results from phase III THALES trial
Open Orphan announces £2.5m influenza challenge study contract
Company subsidiary hVIVO will conduct study with a US biotech
Vertex’s Kalydeco scores another label extension in EU
Label extension includes eligible infants aged four months or older
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis
Around 400,000 people in the UK are living with rheumatoid arthritis
Lynparza scores two new EU approvals
PARP inhibitor approved for new ovarian and prostate cancer indications
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study
Synovitis (joint lining inflammation) can lead to joint damage in psoriatic arthritis patients
NHS at a ‘critical point’ as COVID-19 cases climb
NHS Confederation chief exec calls on public to support non-COVID services
Oncology development programme launches at UK life science campus
National programme launched by Bruntwood SciTech at Alderley Park
AZ’s Forxiga wins EU approval for heart failure
SGLT2 inhibitor approved for heart failure with reduced ejection fraction
Sobi launches thrombocytopenia drug Doptelet in EU
Drug will be launched in the UK first
GW Pharma begins recruitment for US-based Sativex trial
Trial will evaluate Sativex (nabiximols) for multiple sclerosis spasticity
Bristol Myers Squibb’s psoriasis med hits the mark in phase III
Deucravacitinib demonstrated superiority to placebo and Otezla in phase III
